|
|
Hokkaido University Collection of Scholarly and Academic Papers >
Faculty of Pharmaceutical Sciences >
Peer-reviewed Journal Articles, etc >
Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer
This item is licensed under:Creative Commons Attribution 4.0 International
| Title: | Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer |
| Authors: | Watanabe, Yuko Browse this author | | Saito, Yoshitaka Browse this author →KAKEN DB | | Mitamura, Takashi Browse this author →KAKEN DB | | Takekuma, Yoh Browse this author →KAKEN DB | | Sugawara, Mitsuru Browse this author →KAKEN DB |
| Keywords: | Aprepitant | | Carboplatin | | TC | | Nausea | | CINV | | MEC |
| Issue Date: | 1-Jun-2021 |
| Publisher: | BioMed Central |
| Journal Title: | Journal of pharmaceutical health care and sciences |
| Volume: | 7 |
| Start Page: | 21 |
| Publisher DOI: | 10.1186/s40780-021-00204-z |
| Abstract: | Background: Recently, aprepitant has been recommended in carboplatin-based regimens, but there are limited
reports on the efficacy of administering aprepitant, palonosetron, and dexamethasone (DEX) in carboplatincontaining
regimens. Moreover, because aprepitant is an expensive drug, confirming its effectiveness is very
important from the medical cost perspective. In this study, we examined the efficacy of prophylactically
administered aprepitant, palonosetron and DEX, in paclitaxel and carboplatin (TC) combination chemotherapy.
Methods: Patients with gynecologic cancer who were treated with paclitaxel (175 mg/m2) and carboplatin (area
under the curve, AUC = 5–6) combination chemotherapy were retrospectively evaluated. The complete response
(CR) rate, severity of nausea, and incidence of anorexia in the first course were compared between patients who
did not receive aprepitant (control group) and those who received (aprepitant group).
Results: The 106 patients were divided into two groups, consisting of 52 and 54 the control and aprepitant groups,
respectively, and the patient background showed no significant difference between both groups. The CR rate of
the overall phase between the control and aprepitant groups was 73.1 vs. 74.1%, that in the acute phase was 98.1
vs. 100%, and in the delayed phase was 75.0 vs. 74.1%, respectively, without any significant difference. The severity
of nausea and incidence of anorexia were also not significantly different between both groups.
Conclusions: The results of the study suggest that adding aprepitant to palonosetron and DEX does not prevent
carboplatin-induced nausea and vomiting in gynecologic cancer patients. Therefore, adding aprepitant to
palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer. |
| Rights: | https://creativecommons.org/licenses/by/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/82158 |
| Appears in Collections: | 薬学研究院 (Faculty of Pharmaceutical Sciences) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
|
